Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NTRX 07

Next Previous
Drug Profile

NTRX 07

Alternative Names: MDA-7; NTRX-07

Latest Information Update: 28 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Cleveland Clinic; NeuroTherapia; University of Texas M. D. Anderson Cancer Center
  • Class Analgesics; Antidementias; Benzofurans; Benzyl compounds; Heterocyclic compounds; Neuroprotectants; Piperidines; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • No development reported Neuropathic pain

Most Recent Events

  • 28 May 2026 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO)
  • 07 Apr 2026 Preliminary pharmacodynamics and adverse events data from a phase-IIa trial in Alzheimer's disease released by NeuroTherapia
  • 07 Apr 2026 NeuroTherapia completes a phase-IIa trial in Alzheimer's disease (In the elderly) in Hungary, Poland, and the Czech Republic (PO), (NCT07058688)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top